Post #7 by LucidDreamer on the Esperion Therapeutics board

Stocks A to Z / Stocks E / Esperion Therapeutics (ESPR)

Unthreaded | Threaded | Whole Thread (2)

Post Reply | Report Post | Recommend It!

No. of Recommendations: 6

https://www.esperion.com/news-releases/news-releas...

“This real-world study adds to the body of clinical evidence and further underscores the therapeutic role for bempedoic acid in helping patients achieve their LDL-C goals, which is particularly important as cardiovascular disease remains the number one cause of death in Europe and the United States,” said Sheldon Koenig, President and CEO of Esperion. “We are very pleased with DSE’s continued progress and look at successes in the growing adoption of bempedoic acid in Europe and other international markets as a potential proxy for the significant market opportunity in the United States.”

Dreamer

Print the post

Post Reply | Report Post | Recommend It!

No. of Recommendations: 3

not sure if related or not, but stock up 56% (as of this typing) from about $1.60 to $2.54 since Oct 1st or so.

European partner growing strong (DSE).
Otsuka partner for Japan almost ready to start selling now (2025 start) which triggers milestones and royalties.

They should address Nov 2025 Note soon.

At ER conf call last week they mention partnership for Canada is imminent.

US sales up 50% Y/Y.
Scripts up 46% Y/Y which is 4th straight Q of a minimum 42% Y/Y growth.

US sales on pace for $120m in 2024.

Market Cap is still only 500m????

Do your own DD and invest accordingly.

Dreamer

Print the post

Post New

Unthreaded | Threaded | Whole Thread (2)

Prev | Next

Announcements

Esperion Therapeutics FAQ

Contact Shrewd'm
Contact the developer of these message boards.

A community forum supporting civilized, and highly helpful, self-educating investors that come together for Shrewdness and merry spirits. These message boards closely follow the look and feel of the old message boards at boards.fool.com prior to the boards redirected to discussion.fool.com. Shrewd'm is not affiliated with the comprehensive and excellent investment website, The Motley Fool (TMF), in any way. The Shrewd commmunity here has owed, and continues to owe, gratitude to The Motley Fool for nurturing a culture of jovial irreverence towards Wall St, and that tradition will continue here.